نتائج البحث - "Gonzalez-del-Alba, Aranzazu"

1

دورية أكاديمية

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)

المساهمون: Gillessen, Silke, Procopio, Giuseppe, Hayoz, Stefanie, Kremer, Eloïse, Schwitter, Michael, Caffo, Orazio, Lorente, David, Pedrazzini, Augusto, Roubaud, Guilhem, Nenan, Soazig, Omlin, Aureliu, Buttigliero, Consuelo, Delgado Mingorance, Juan Ignacio, González-del-Alba, Aránzazu, Delgado, Maria Teresa, Nole, Franco, Turco, Fabio, Pereira Mestre, Ricardo, Ribi, Karin, Cathomas, Richard

مصطلحات موضوعية: Darolutamide, Metastatic Castration-Resistant Prostate Cancer, Nonprogressive Disease, After Taxane Treatment, SAKK 08/16

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36753698; volume:Feb 8; firstpage:1; lastpage:9; numberofpages:9; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/2318/1893660Test

الإتاحة: https://doi.org/10.1200/JCO.22.01726Test
https://hdl.handle.net/2318/1893660Test

View record in BASE

2

دورية أكاديمية

A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide

المصدر: Prostate , 83 (4) pp. 376-384. (2023)

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, Urology & Nephrology, AR gain, AR-V7, CTCs, enzalutamide, prostate cancer, TMPRSS2-ERG, CIRCULATING TUMOR-CELLS, GENE STATUS, ANDROGEN RECEPTOR, CLINICAL-TRIALS, ABIRATERONE, SURVIVAL, SURROGATE, TMPRSS2, FUSION, MEN

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10164231/1/A%20correlative%20biomarker%20study%20and%20integrative%20prognostic%20model.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10164231Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10164231/1/A%20correlative%20biomarker%20study%20and%20integrative%20prognostic%20model.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10164231Test/

View record in BASE

3

دورية أكاديمية

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

المساهمون: Astellas Pharma, Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Fundación CRIS contra el Cáncer

مصطلحات موضوعية: Prostate cancer, AR gain, AR-V7, CTCs, TMPRSS2-ERG, Enzalutamide

وصف الملف: application/pdf

العلاقة: Publisher's version; The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1002/pros.24469; https://doi.org/10.1002/pros.24469Test; Sí; The Prostate 83(4): 376-384 (2023); http://hdl.handle.net/10261/333013Test; http://dx.doi.org/10.13039/501100004948Test; http://dx.doi.org/10.13039/501100003751Test; http://dx.doi.org/10.13039/501100004587Test; 2-s2.0-85145039209; https://api.elsevier.com/content/abstract/scopus_id/85145039209Test

الإتاحة: https://doi.org/10.1002/pros.2446910.13039/50110000494810.13039/50110000375110.13039/501100004587Test
http://hdl.handle.net/10261/333013Test
https://api.elsevier.com/content/abstract/scopus_id/85145039209Test

View record in BASE

4

دورية أكاديمية

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

المؤلفون: Méndez-Vidal, María José, Lázaro Quintela, Martin, Lainez-Milagro, Nuria, Perez-Valderrama, Begoña, Suárez Rodriguez, Cristina, Arranz Arija, José Ángel, Peláez Fernández, Ignacio, Gallardo Díaz, Enrique, Lambea Sorrosal, Julio, González-del-Alba, Aránzazu

المصدر: Clinical and Translational Oncology ; volume 25, issue 9, page 2732-2748 ; ISSN 1699-3055

مصطلحات موضوعية: Cancer Research, Oncology, General Medicine

الإتاحة: https://doi.org/10.1007/s12094-023-03276-5Test

View record in BASE

5

دورية أكاديمية

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

مصطلحات موضوعية: AR gain, AR-V7, CTCs, Enzalutamide, Prostate cancer, TMPRSS2-ERG

وصف الملف: application/pdf

العلاقة: Ministerio de Economía y Competitividad BA16/00038; Instituto de Salud Carlos III PI18/00883; The Prostate; Vol. 83 (december 2022); https://ddd.uab.cat/record/281329Test; urn:10.1002/pros.24469; urn:oai:ddd.uab.cat:281329; urn:pmcid:PMC10107622; urn:pmc-uid:10107622; urn:pmid:36564933; urn:oai:pubmedcentral.nih.gov:10107622

الإتاحة: https://ddd.uab.cat/record/281329Test

View record in BASE

6

دورية أكاديمية

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)

المؤلفون: Pérez-Valderrama, Begoña, González‑del‑Alba, Aránzazu, Morales Barrera, Rafael, Peláez Fernández, Ignacio, Vázquez, Sergio, Caballero Díaz, Cristina

المساهمون: Institut Català de la Salut, Valderrama BP Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. González-Del-Alba A Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. Morales-Barrera R Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peláez Fernández I Medical Oncology Department, Hospital Universitario de Cabueñes, Gijón, Asturias, Spain. Vázquez S Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain. Caballero Díaz C Medical Oncology Department, Hospital General Universitario de Valencia, Centro de Investigación Biomédica de Red en Cáncer (CIBERONC), Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Quimioteràpia combinada, Bufeta - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias de la vejiga, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante

وصف الملف: application/pdf

العلاقة: Clinical and Translational Oncology;24; https://doi.org/10.1007/s12094-022-02815-wTest; Valderrama BP, González-Del-Alba A, Morales-Barrera R, Peláez Fernández I, Vázquez S, Caballero Díaz C, et al. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). Clin Transl Oncol. 2022 Apr;24:613–24.; https://hdl.handle.net/11351/7997Test; 000773969100003

الإتاحة: https://doi.org/10.1007/s12094-022-02815-wTest
https://hdl.handle.net/11351/7997Test

View record in BASE

7

دورية أكاديمية

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

المؤلفون: Carles Galceran, Joan, Mellado, Begoña, Méndez-Vidal, María J., Vázquez, Sergio, Gonzalez-del-Alba, Aranzazu, Morales Barrera, Rafael, Alonso-Gordoa, Teresa

المساهمون: Institut Català de la Salut, Carles J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Alonso-Gordoa T Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. Mellado B Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Méndez-Vidal MJ Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain. Reina Sofía University Hospital (HURS), Córdoba, Spain. Vázquez S Lucus Augusti University Hospital, Lugo, Spain. González-del-Alba A Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain. Morales-Barrera R Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pròstata - Càncer - Tractament, Antiandrògens - Ús terapèutic, Avaluació de resultats (Assistència sanitària), DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Androgen Antagonists, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de andrógenos, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: European Journal of Cancer;173; https://doi.org/10.1016/j.ejca.2022.06.057Test; Carles J, Alonso-Gordoa T, Mellado B, Méndez-Vidal MJ, Vázquez S, González-del-Alba A, et al. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer. 2022 Sep;173:317–26.; https://hdl.handle.net/11351/8356Test

الإتاحة: https://doi.org/10.1016/j.ejca.2022.06.057Test
https://hdl.handle.net/11351/8356Test

View record in BASE